Evidence map›Paper›PMID 27903593›Full record

ReviewClinical microbiology reviews2017

Respiratory Syncytial Virus: Infection, Detection, and New Options for Prevention and Treatment.

Cameron Griffiths, Steven J Drews, David J Marchant

Registry-linked trialOpen access · bronzeAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Clinical microbiology reviews, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05164692 (Application of LiveSpo Navax in Treatment of Acute Respiratory Disease in Children Infected With Respiratory Syncytial Virus), which is not on this map. Cited by 330 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
330citing papers in PubMed, 5 pooled it
24.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05164692 nacompletednot on this mapstarted 2020, after this paper: background citation

Application of LiveSpo Navax in Treatment of Acute Respiratory Disease in Children Infected With Respiratory Syncytial Virus

TypeinterventionalSponsorNational Children's Hospital, VietnamRan2020 to 2021Enrolled100ConditionsAcute Respiratory Tract InfectionsArmsLiveSpo Navax, 0.9% NaCl physiological saline
3 · Its place in the literature

Who cites it

330 citing papers in PubMed, 5 syntheses or guidelines pooled it, 575 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Review
  13. Observational
  14. Review
  15. Review
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article

270 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Cameron GriffithsLi Ka Shing Institute of Virology, Department of Medical Microbiology and Immunology, University of Alberta, Edmonton, Alberta, Canada.
Steven J DrewsAlberta Provincial Laboratory for Public Health, ProvLab, Edmonton, Alberta, Canada steven.drews@albertahealthservices.ca marchant@ualberta.ca.
David J MarchantLi Ka Shing Institute of Virology, Department of Medical Microbiology and Immunology, University of Alberta, Edmonton, Alberta, Canada steven.drews@albertahealthservices.ca marchant@ualberta.ca.
University of Alberta · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Respiratory syncytial virus (RSV) infection is a significant cause of hospitalization of children in North America and one of the leading causes of death of infants less than 1 year of age worldwide, second only to malaria. Despite its global impact on human health, there are relatively few therapeutic options available to prevent or treat RSV infection. Paradoxically, there is a very large volume of information that is constantly being refined on RSV replication, the mechanisms of RSV-induced pathology, and community transmission. Compounding the burden of acute RSV infections is the exacerbation of preexisting chronic airway diseases and the chronic sequelae of RSV infection. A mechanistic link is even starting to emerge between asthma and those who suffer severe RSV infection early in childhood. In this article, we discuss developments in the understanding of RSV replication, pathogenesis, diagnostics, and therapeutics. We attempt to reconcile the large body of information on RSV and why after many clinical trials there is still no efficacious RSV vaccine and few therapeutics.

Indexed as

Antiviral AgentsClinical Trials as TopicHumansPoint-of-Care SystemsRespiratory Syncytial VirusesRespiratory Syncytial Virus InfectionsViral VaccinesVirulenceAntiviral AgentsViral Vaccinesdiagnosticsepidemiologyexperimental therapeuticsimmunizationrespiratory syncytial virusviral pathogenesis

Identifiers

PMID27903593
PMCPMC5217795
OpenAlexW2558274900

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.